KROS — Keros Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1664710 ·
Last close
$11.23
Market Cap
$222.26M
52W High
$15.11
52W Low
$9.79
ADV30
336,338
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 367,000 | — | -25,877,000 | -23,708,000 | 312,293,000 | 281,497,000 | 26,663,000 |
| Dec 2025 | 385,000 | — | -29,270,000 | -23,461,000 | 338,021,000 | 287,415,000 | 34,889,000 |
| Sep 2025 | 14,262,000 | — | -15,384,000 | -7,280,000 | 742,783,000 | 693,472,000 | 39,203,000 |
| Jun 2025 | 18,168,000 | — | -39,817,000 | -30,696,000 | 757,165,000 | 690,215,000 | 50,431,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$107,505,000
Investing CF
$-1,551,000
Financing CF
$-378,470,000
CapEx
$-1,551,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$1.82
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-481,765,000
Inventory
—
Receivables
$6,372,000
ST Investments
—
EBIT TTM
$67,569,000
Pretax Income TTM
$91,897,000
Interest Exp TTM
—
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$33,182,000
EBITDA
$-105,780,000
Free Cash Flow
$-37,688,500
Enterprise Value
$-42,923,672
Total Cash
$281,496,992
Total Debt
$16,311,000
Shares Out
19,791,837
Trailing EPS
$-2.53
Book Value
$14.47
ROE
-16.8%
ROA
-12.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 244,061,000 | 67,569,000 | 87,014,000 | 338,021,000 | 34,889,000 | — | 107,505,000 |
| Dec 2024 | 3,550,000 | -209,595,000 | -187,353,000 | 615,886,000 | 44,333,000 | — | -160,869,000 |
| Dec 2023 | 151,000 | -167,541,000 | -152,992,000 | 370,025,000 | 37,812,000 | — | -124,508,000 |
| Dec 2022 | 0 | -107,709,000 | -104,679,000 | 306,781,000 | 29,358,000 | — | -70,062,000 |
TTM Snapshot
Revenues TTM
$396,000
NetIncome TTM
$-136,202,000
OpCashFlow TTM
$0
Assets (Latest)
$615,886,000
Forward EPS
$-6.22
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RNA | Atrium Therapeutics, Inc. | $223.40M | $13.06 | — |
| HELP | CYBIN INC. | $221.03M | $4.43 | — |
| NKTX | Nkarta, Inc. | $218.93M | $3.06 | — |
| NBP | NovaBridge Biosciences | $215.11M | $1.86 | — |
| CNTN | Canton Strategic Holdings, Inc. | $229.66M | $3.29 | — |
News headlines (Yahoo Finance, 1h cache)
KROS Turns to Next Wave of TGF-Beta Muscle Therapies
2026-05-22 15:10 · Yahoo
Should You Buy KROS After Q1 Miss and Takeda Deal Reset?
2026-05-22 15:06 · Yahoo
KROS Stock Guide to Rinvatercept in DMD and ALS for 2026
2026-05-22 15:03 · Yahoo
Earnings Release: Here's Why Analysts Cut Their Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target To US$21.20
2026-05-17 13:36 · Yahoo
Keros Q1 Loss Wider Than Expected, Revenues Plunge Year Over Year
2026-05-15 16:08 · Yahoo
Keros Therapeutics, Inc. (KROS) Reports Q1 Loss, Misses Revenue Estimates
2026-05-14 13:10 · Yahoo
Keros Therapeutics Reports Recent First Quarter 2026 Financial Results
2026-05-14 12:00 · Yahoo
Aytu BioPharma, Inc. (AYTU) Reports Q3 Loss, Tops Revenue Estimates
2026-05-13 21:35 · Yahoo
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates
2026-05-11 21:10 · Yahoo
KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment
2026-04-20 15:41 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.